Tokyo, July 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058615) titled 'Exploration of novel biomarker for the eligibility of neoadjuvant chemotherapy followed by operation for the patient with biliary pancreatic cancer' on July 28.
Study Type:
Observational
Primary Sponsor:
Institute - Yamaguchi university Hospital
Condition:
Condition - pancreatic cancer,bile duct cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Multimodal treatment strategies for pancreatic and biliary tract cancers have yet to be fully established. This study aims to comprehensively investigate prognostic factors that influence the resectability and survival outcomes of neoadjuvant chemotherapy (NAC) followed by surgery. We will evaluate therapeutic approaches from the perspectives of drug-related, tumor-related, and host-related factors.
Basic objectives2 - Safety
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Eligible patients must (1) be of any sex, (2) be at least 20 years old at the time of consent, and (3) have received a full explanation of the study, understood its content, and voluntarily signed a written informed consent form.
Key exclusion criteria - Exclusion criteria include: (1) ECOG Performance Status of 3 or 4, (2) diagnosis of dementia, and (3) any case in which the investigator or sub-investigator determines the patient to be inappropriate for study enrollment.
Target Size - 100
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2020 Year 04 Month 22 Day
Date of IRB - 2020 Year 04 Month 22 Day
Anticipated trial start date - 2020 Year 04 Month 22 Day
Last follow-up date - 2032 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066929
Disclaimer: Curated by HT Syndication.
